Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Symbotic Inc (SYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Symbotic Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Symbotic Inc trades at $41.81 (market cap $5.26B). The key difference: Symbotic Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | SYM | |
|---|---|---|
Market Cap | $4.49B | $5.26B |
Sector | Health | Technology |
52-Week High | $28.06 | $87.30 |
52-Week Low | $20.06 | $38.57 |
Enterprise Value | $3.69B | $3.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SYM trades at $44.46, up 4.02% in the last session, with a neutral technical signal and bearish moving averages. The stock shows mixed earnings, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, while revenue grew to $2.25B in 2025. Recent news highlights the acquisition of ARMS Innovations, expanding its warehouse automation solutions, amid high investor interest in robotics stocks.
The outlook is cautiously optimistic with a consensus price target of $57.50, but risks include negative net income margins and high valuation multiples like EV/EBITDA of 246.96. Upside potential hinges on execution in the growing automation market, while downside risks involve competitive pressures and profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
